SCHEDULE: Orbis BioCapital Reports 9.98% Stake in Universe Pharmaceuticals

Orbis BioCapital Limited and Chunhua Zheng have jointly reported beneficial ownership of 9.98% of Universe Pharmaceuticals INC's Class A ordinary shares.

Summary

• Orbis BioCapital Limited and Chunhua Zheng have jointly filed a Schedule 13G, indicating their beneficial ownership of 499,926 Class A ordinary shares of Universe Pharmaceuticals INC.
• This holding represents 9.98% of the total outstanding Class A ordinary shares.
• The filing specifies that Orbis BioCapital Limited is a company organized in the British Virgin Islands and is wholly owned and controlled by Chunhua Zheng, a citizen of the People's Republic of China.
• The shares are held with shared voting and dispositive power between Orbis BioCapital Limited and Chunhua Zheng.
• The total number of outstanding Class A ordinary shares as of July 27, 2026, was 5,008,313.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership that crosses a reporting threshold. There are no new financial results or strategic announcements.

Positives

• Clear disclosure of beneficial ownership, enhancing transparency for investors.
• The reporting persons are acting in concert, as evidenced by the joint filing agreement.

Negatives

• No new financial performance data or strategic initiatives are disclosed in this filing.
• The filing does not provide insight into the investment strategy or future intentions of the reporting persons.

Risks

• Potential for increased shareholder activism or influence by Orbis BioCapital Limited and Chunhua Zheng, given their significant stake.
• The concentration of ownership could lead to shifts in corporate control or strategic direction if the reporting persons decide to exert influence.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategies.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders crossing ownership thresholds. This filing indicates a notable stake in Universe Pharmaceuticals, which could signal increased investor interest or potential for strategic influence within the pharmaceutical sector.

Stakeholder Impact

• Shareholders: May see increased volatility or strategic shifts due to the significant stake held by Orbis BioCapital and Chunhua Zheng.
• Management: May need to engage with the new significant shareholder regarding corporate strategy and governance.

Next Steps

• Monitor future filings from Orbis BioCapital Limited and Chunhua Zheng for any changes in beneficial ownership.
• Observe Universe Pharmaceuticals INC's strategic decisions and corporate governance for any potential influence from the new significant shareholder.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Class A ordinary shares, Universe Pharmaceuticals, Orbis BioCapital, Chunhua Zheng, shareholder, investment